Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening.
about
Emerging and future therapies for hemophiliaThe current state of adverse event reporting in hemophilia.The safety of pharmacologic options for the treatment of persons with hemophilia.The national haemophilia program standards, evaluation and oversight systems in the United States of AmericaPrinciples of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in ItalyHemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand diseaseInnovative approach for improved rFVIII concentrate.Current treatment options for hereditary angioedema due to C1 inhibitor deficiency.Emerging drugs for the treatment of hemophilia A and B.Identification of recombination in the NS1 and VPs genes of parvovirus B19.Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey.Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice.Managing haemophilia for life: 4th Haemophilia Global Summit.Pharmacokinetics of recombinant human antithrombin in delivery and surgery patients with hereditary antithrombin deficiency.Pharmacokinetic drug evaluation of albutrepenonacog alfa (CSL654) for the treatment of hemophilia.Simoctocog alfa for the treatment of hemophilia A.Human parvovirus B19 and parvovirus 4 among Iranian patients with hemophilia.Parvovirus B19: What Is the Relevance in Transfusion Medicine?Factors affecting the quality, safety and marketing approval of clotting factor concentrates for haemophilia
P2860
Q26781143-B9232E68-12F6-4892-B8C5-FC5FEFDC1909Q30239952-B508EDD1-E2C1-4A9E-909A-35B834AF08E8Q30249200-36AFA9D0-B0DC-4BE9-9C21-E577D203033FQ33708891-EBFD9326-981C-4662-B7E8-DD0001B25729Q34416394-5A98395C-683B-438C-A82A-44A1B4E1BE62Q36193201-D402A397-D9A0-4831-BB8C-E411D50F4B70Q38207134-529C5EC3-C7A2-4FAD-AC97-90B758C3CDC9Q38619062-15E7D0D7-98B3-4868-941E-C652041393E7Q38933707-E7CAF97E-7FC0-4BCA-BF6C-32E315D217A4Q40983850-C936D341-71DD-4AFF-8139-F36FAB36D7D6Q42236600-B8CC942A-408E-4E34-8CE1-4DB16140E982Q42958772-854B0723-A55C-4D65-8EC9-CDAA72AD4B12Q44122887-74C09B74-3B8A-4F4C-974E-C21BDA95D817Q44772500-17EAF3F1-5C6E-4FFA-AC36-9B96C2F75D05Q45858664-A37A799E-247A-423C-9923-70803B311022Q45873366-A27339A1-87C9-4C00-8730-D94E53C21F83Q47553734-F5840BB4-4D11-486A-96C7-AD8A574BABC0Q49416500-D68EE3D9-6B26-4D63-BD32-E571D9B76A03Q58701325-D9DAA206-E62B-4649-B94A-F91CE90985AC
P2860
Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Evidence for the transmission ...... f nucleic acid test screening.
@ast
Evidence for the transmission ...... f nucleic acid test screening.
@en
type
label
Evidence for the transmission ...... f nucleic acid test screening.
@ast
Evidence for the transmission ...... f nucleic acid test screening.
@en
prefLabel
Evidence for the transmission ...... f nucleic acid test screening.
@ast
Evidence for the transmission ...... f nucleic acid test screening.
@en
P2093
P2860
P1433
P1476
Evidence for the transmission ...... f nucleic acid test screening.
@en
P2093
Brenda Riske
Christine De Staercke
Craig Kessler
Hernan Sabio
J Michael Soucie
Jerry Powell
Marilyn J Manco-Johnson
Meera B Chitlur
Meredith Pyle
Michael Recht
P2860
P304
P356
10.1111/J.1537-2995.2012.03907.X
P577
2012-09-24T00:00:00Z